Cargando…
Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
Although breast cancer has a good prognosis compared with various cancers, metastatic breast cancer has an aggressive disease course and remains incurable. Therefore, treatment of early breast cancer to prevent recurrence and metastasis is crucial. Recently, the development of anti-cancer drugs, suc...
Autores principales: | Jeong, Jae Ho, Kim, Sung-Bae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634352/ https://www.ncbi.nlm.nih.gov/pubmed/36327625 http://dx.doi.org/10.1016/j.breast.2022.10.015 |
Ejemplares similares
-
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
por: Shastry, Mythili, et al.
Publicado: (2022) -
Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022) -
How I treat HER2-low advanced breast cancer
por: Schlam, Ilana, et al.
Publicado: (2023) -
Antibody Drug Conjugates of Near-Infrared Photoimmunotherapy (NIR-PIT) in Breast Cancers
por: Cui, Yingshu, et al.
Publicado: (2023) -
Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer
por: Grinshpun, Albert
Publicado: (2023)